NP/PA Connect
News
Media
Around the PracticeBetween The LinesCase-Based Peer PerspectiveClinical Case CollectiveDermViewExpert PerspectivesFellows Face OffFrontline ForumMedical World NewsPatient PerspectivesPodcastsReadout360Recognize and Refer
Conferences
Conference CoverageConference Listing
Events
Case-Based Roundtable
Publication
Dermatology Times
More
CME/CE
Resources
DermIQInteractive ToolsJob BoardPartner PerspectivesPerspectives in DermatologyPollsSponsored ContentSponsored ResourcesSpot Test
Editorial Advisory Board
Partners

Subscribe

  • News
  • Media
  • Conferences
  • Events
  • Publication
  • CME/CE
  • Resources
  • Editorial Advisory Board
  • Partners
  • Subscribe
  • Acne
  • Actinic Keratosis
  • Aesthetics
  • Alopecia
  • Atopic Dermatitis
    • Biologic Treatments for Moderate to Severe Atopic Dermatitis
  • Buy-and-Bill
  • COVID-19
  • Case-Based Roundtable
  • Chronic Hand Eczema
  • Chronic Spontaneous Urticaria
  • Drug Watch
  • Eczema
  • General Dermatology
  • Hidradenitis Suppurativa
  • Melasma
  • Pediatric Dermatology
  • Pigmentary Disorders
  • Practice Management
  • Precision Medicine and Biologics
  • Prurigo Nodularis
  • Psoriasis
    • Emerging Therapies Plaque Psoriasis
    • Treatments for Plaque Psoriasis
  • Psoriatic Arthritis
  • Rare Disease
  • Rosacea
  • Skin Cancer
    • Skin Cancer (Nonmelanoma)
  • Vitiligo
  • Wound Care
Spotlight -
Derm NP/PA Connect
Advertisement

Joshua Burshtein, MD

Advertisement

Articles by Joshua Burshtein, MD

Highlighting Major Breakthroughs for Atopic Dermatitis and Psoriasis in 2025

ByJoshua Burshtein, MD
December 17th 2025

Discover the latest breakthroughs in atopic dermatitis and psoriasis treatments for 2025, enhancing patient care and individualizing therapy options.

Advertisement

Latest Updated Articles

  • Highlighting Major Breakthroughs for Atopic Dermatitis  and Psoriasis in 2025
    Highlighting Major Breakthroughs for Atopic Dermatitis and Psoriasis in 2025

    Published: December 17th 2025 | Updated:



Advertisement
Advertisement

Trending on Dermatology Times

1

Oruka Reports Positive Interim Phase 1 Data for ORKA-002, Advances ORKA-001

2

Recludix Pharma’s REX-8756 for Type 2 Inflammatory Diseases Enters First Human Trials

3

Alpha Tau Submits First PMA Module to FDA for Novel cSCC Treatment, Alpha DaRT

4

Expert Panel Provides Clinical Guidance for the Use of Trifarotene in Malaysian Acne Care

5

Next-Generation IL-4Rα Targeting and Potential Dermatologic Implications

  • About
  • Advertise
  • Contact Us
  • Job Board
  • Do Not Sell My Information
  • Terms and Conditions
  • Privacy Policy
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us